Organon & Co. (NYSE:OGN) Hits New 12-Month High – What’s Next?

Organon & Co. (NYSE:OGN)’s stock price reached a new 52-week high on Wednesday. The company traded as high as $13.88 and last traded at $13.8550, with a volume of 151,651 shares traded. The stock had previously closed at $13.85.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Five analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $11.40.

Organon & Co. Trading Up 0.0%

The firm has a market cap of $3.64 billion, a price-to-earnings ratio of 18.23, a PEG ratio of 1.27 and a beta of 1.53. The company has a debt-to-equity ratio of 7.11, a quick ratio of 1.44 and a current ratio of 2.02. The business has a fifty day moving average of $13.75 and a two-hundred day moving average of $11.53.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Friday, October 30th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.06. The firm had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.58 billion. Organon & Co. had a return on equity of 82.06% and a net margin of 3.49%. As a group, equities analysts expect that Organon & Co. will post 3.24 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Monday, November 9th will be given a $0.02 dividend. The ex-dividend date is Monday, November 9th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. Organon & Co.’s dividend payout ratio (DPR) is currently 10.53%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Allied Private Wealth LLC purchased a new position in Organon & Co. during the 2nd quarter valued at about $33,000. WNY Asset Management LLC acquired a new position in Organon & Co. during the first quarter worth about $64,000. Nykredit A S acquired a new position in Organon & Co. during the second quarter worth about $76,000. GAMMA Investing LLC lifted its holdings in shares of Organon & Co. by 69.8% in the second quarter. GAMMA Investing LLC now owns 5,782 shares of the company’s stock valued at $78,000 after purchasing an additional 2,376 shares in the last quarter. Finally, HB Wealth Management LLC lifted its holdings in shares of Organon & Co. by 39.1% in the first quarter. HB Wealth Management LLC now owns 15,733 shares of the company’s stock valued at $94,000 after purchasing an additional 4,423 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a global health care company focused on improving the health and quality of life of women throughout their lives. The company develops, manufactures and commercializes prescription medicines and other health care products, with operations serving patients and health care providers in markets around the world.

Organon’s women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines and technologies related to fertility, pregnancy and other reproductive health needs.